US 11,939,296 B2
Anti-cancer compounds
Michael Kassiou, New South Wales (AU); William Jorgensen, New South Wales (AU); and Lenka Munoz, New South Wales (AU)
Assigned to The University of Sydney, New South Wales (AU)
Filed by The University of Sydney, New South Wales (AU)
Filed on Aug. 30, 2022, as Appl. No. 17/899,297.
Application 17/899,297 is a continuation of application No. 16/965,398, granted, now 11,472,774, previously published as PCT/AU2019/050073, filed on Jan. 1, 2019.
Claims priority of application No. 2018900315 (AU), filed on Feb. 1, 2018.
Prior Publication US 2023/0028660 A1, Jan. 26, 2023
Int. Cl. A61K 31/4409 (2006.01); A61K 31/4406 (2006.01); A61K 31/4965 (2006.01); C07D 213/75 (2006.01); C07D 213/82 (2006.01); C07D 241/24 (2006.01); C07D 307/66 (2006.01); C07D 317/66 (2006.01)
CPC C07D 213/75 (2013.01) [A61K 31/4406 (2013.01); A61K 31/4409 (2013.01); A61K 31/4965 (2013.01); C07D 213/82 (2013.01); C07D 241/24 (2013.01); C07D 307/66 (2013.01); C07D 317/66 (2013.01)] 16 Claims
 
1. A method of treating a proliferative disease, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
X is C3 alkenyl;
Y is

OG Complex Work Unit Chemistry
W is O;
R2 is H, alkyl or alkenyl;
Z is a heteroaryl group, which heteroaryl group is optionally substituted with a hydroxyl, a halo group or a heteroalkyl group;
R1 is phenyl, which is optionally substituted with a halo group or a heteroalkyl group;
Ar is phenyl, wherein R1 and X are para to each other around the phenyl of Ar,
or a pharmaceutically acceptable salt or prodrug thereof,
wherein the proliferative disease is a cancer selected from brain cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, uterine cancer, skin cancer, colon cancer and bladder cancer.